Participated · Seed · Jul 2026

Founded in 2020 and based in St. John’s, SiftMed builds AI-powered software that ingests, structures and analyzes thousands of pages of medical records to surface supporting evidence for medical claims reviews. The platform aims to speed decisions that can take human reviewers hours to days down to as little as two hours, depending on the review type, while reducing missed facts. SiftMed’s 30-person team includes clinicians and former Verafin staff, and the company’s founders include CEO Holly Hill and co-founder Dr. Jeremie Larouche. Staircase Ventures has highlighted strong commercial traction, saying SiftMed is more than doubling revenue every six months. The startup has raised nearly CAD $11 million to date and plans to use its latest CAD $5 million seed round to expand its product reach and pursue a larger Series A within 12 to 18 months.

Participated · Seed · Jul 2026

GroundedAI develops an AI platform aimed at tackling the complexity of underground infrastructure and related engineering challenges. The company’s founders include Shelby Yee and Stuart Bourne, who were highlighted in the funding announcement. Public commentary around the company situates its work against the $200B+ annual global spend on underground infrastructure and compares cost inefficiencies like NYC’s subway build costs. The platform is presented as designed to meet the complexity of those systems, though specific product details and metrics were not disclosed. GroundedAI recently raised a $2M Seed round announced with BoxOne Ventures and several participating investors.

Led · Equity · Mar 2026

Coral offers an integrated virtual clinic combining medical expertise, advanced technology and health coaching to provide personalized, evidence-based plans for menopause symptom management, weight loss and midlife longevity. The platform markets clinical outcomes including that 80% of members report significantly improved mental well-being and over 70% see a meaningful reduction in perimenopause and menopause symptoms within 90 days. Founded in 2024 and headquartered in Montreal, Coral launched its service one year prior to this funding. Financially, the company has raised over CAD $8 million in total capital following the latest CAD $4 million acceleration round. Coral plans to use the fresh capital to expand nationally, grow its clinical teams, and further develop its AI capabilities to scale its integrated care model.

Participated · Equity · Nov 2025

NLPatent offers an AI-powered patent research platform designed to accelerate and simplify the process of locating and analyzing prior art for legal departments, law firms, and technology companies. By leveraging machine learning, the product aims to deliver faster and more accurate search results than traditional keyword-based tools. The company positions itself within the growing legal-tech segment, serving clients that require high-volume, high-accuracy patent insights. Its technology is marketed as a way to reduce research time and improve decision-making in intellectual-property workflows. NLPatent recently secured a $3 million funding round, which supplies its current capital base and underscores investor confidence in its approach. Although the article does not disclose revenue, user numbers, or profitability metrics, the new financing suggests continued product enhancement and potential market expansion. The startup’s backers include well-known venture investors focused on both technology and legal-tech sectors.

Participated · Seed · Jun 2025

NiaHealth provides an end-to-end proactive health platform combining clinical-grade biomarker testing, integrations with consumer wearables, continuous glucose monitoring, and 1:1 clinician guidance to help members identify and act on health risks before symptoms appear. The company offers HSA-eligible services and is available across provinces including Ontario, Alberta, British Columbia, Manitoba, Saskatchewan, Nova Scotia, New Brunswick, Newfoundland and Labrador, and Prince Edward Island. Since emerging from stealth earlier this year it has built a waitlist of over 12,000 Canadians, is on track to cross 300K+ biomarker tests by year-end, and has grown users ~30% month-over-month driven largely by referrals. Platform 2.0, launching this summer, expands testing from ~50 to 100+ biomarkers, adds toxic heavy metals, omegas and advanced thyroid tests, and deepens wearable and CGM integrations. The company plans continued product R&D into predictive features and development of human-first, AI-supported clinician tools while scaling user expansion across Canada. Partnerships with the University of Alberta and corporate customers like Ada support its scientific research and employer benefits programs.